# Risedronic acid

## Reosteo 150mg

| TAH Drug Code      | [**OREOS**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OREOS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures, including those of the hip & spine (vertebral compression fractures). Treatment of osteoporosis in men to increase bone mass.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | 150 mg TAB ORALLY taken once monthly or 35 mg TAB orally taken once weekly; take with 6 to 8 ounces of water at least 30 minutes prior to the first food or drink of the day.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Esophageal abnormalities (eg, stricture or achalasia) that delay esophageal emptying. Hypersensitivity to risedronate or any component of the product. Inability to sit or stand upright for at least 30 minutes. Hypocalcemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Common Dermatologic: Rash (osteoporosis, 7.9%; Paget disease, 11.5% ) Gastrointestinal: Abdominal pain (osteoporosis, 2.9% to 12.2% ; Paget disease, 11.5% ), Constipation (osteoporosis, 2.9% to 12.9% ; osteoporosis prevention, 6.5%; Paget disease, 6.6% ), Diarrhea (osteoporosis, 4.9% to 10.8% ; Paget disease, 19.7% ), Indigestion (3.9% to 10.8% ), Nausea (osteoporosis, 3.6% to 3.9% ; osteoporosis prevention, 7.3% to 13.2% ; Paget disease, 9.8% ) Musculoskeletal: Backache (adult, 5.9% to 28% ; pediatric, 17% ) Renal: Urinary tract infectious disease (11.1% ) Other: Influenza-like illness (up to 9.8% ) Serious Cardiovascular: Cardiac dysrhythmia (men, 2% ), Peripheral edema (8.2% ) Dermatologic: Hypersensitivity reaction Musculoskeletal: Arthralgia (osteoporosis, 6.8% to 24.7% ; osteoporosis prevention, 13.9%; Paget disease, 32.8% ), Bone pain (adult, 5.3%; acute phase reaction, 1.1% to 7.6%; pediatric, 10% ), Myalgia (1% to 6.7% ; osteoporosis prevention, 5.1% ), Osteonecrosis of jaw Ophthalmic: Iritis, Uveitis Renal: Nephrolithiasis (3% ) Reproductive: Benign prostatic hyperplasia (5% ) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

